Advertisement

TB Vax for Bladder Cancer

How the bacteria found in a tuberculosis vaccine can improve the outcome of bladder cancer treatment

By | June 6, 2012

image: TB Vax for Bladder Cancer WIKIMEDIA COMMONS

WIKIMEDIA COMMONS,

Bacillus Calmette-Guérin (BCG) is a puny cousin of the bacteria that causes tuberculosis, and as such serves as an excellent vaccine against the disease. But BCG is also used to treat bladder cancer. Research published today (June 5) in Science Translational Medicine reveals how BCG achieves its cancer-fighting performance, and suggests the bug has a better chance of winning if the patient has a prior BCG vaccination.

Since the 1970s, BCG has been used to help prevent bladder cancer from returning after surgical removal. Doctors have simply pumped the bladder full of the bacteria to induce a localized immune response that helps kill cancer cells.

“BCG has always fascinated everybody because here we have what seems like a barbaric approach to treating cancer,” said Michael O’Donnell, a urologist at the University of Iowa who did not participate in the study. “And yet it’s more effective than any chemotherapy we’ve devised.”

Despite the effectiveness of the treatment—it successfully prevents recurrence in some 50–70 percent of patients—no one had much of an idea how it worked. “It’s a piece of the puzzle that’s been lacking for a long time,” said O’Donnell, “until now.”

Matthew Albert of the Pasteur Institute in Paris and colleagues decided to delve into this question in mice. They gave the animals one dose of BCG—called an instillation—per week for 3 weeks and analyzed their bladders at different time points. This treatment protocol mirrored that performed in patients, when at least three and sometimes six instillations are given before a strong immune response develops.

After just one treatment, the BCG bugs had traveled from the bladder to nearby lymph nodes, the team found. However, as seen in patients, it wasn’t until after the third instillation that a strong immune response developed. At that point, large numbers of BCG-specific T cells were found infiltrating the bladder, suggesting “there was an adaptive immune response against the BCG,” said Albert.

The delay between the initial lymph node response and the adaptive response suggested that the first exposure served to prime the T cells, Albert explained. The team thus wondered whether such priming might work just as well, or even better, if BCG was injected under the skin—in the same way that humans receive TB vaccinations.

They injected the mice, waited 3 weeks, and then performed a BCG instillation in the bladder. This single instillation induced an immune response far stronger than that seen when the triple instillation was performed without prior injection, and this response translated into a better tumor-fighting ability. All of the mice that received a BCG injection followed by an instillation were able to battle aggressive cancer cells and survive for 50 days or more, compared to just 20 percent of mice that received the triple instillation therapy.

But, said Albert, “what was really profound was going back to the patient population.” By analyzing bladder cancer patient data, the team found something “striking” he said. Patients with preexisting BCG immunity—caused by either a prior TB vaccination, or a current or prior TB infection—had significantly better recurrence-free survival rates.

Interestingly, prior clinical trials of BCG for bladder cancer had already tested a combined approach of under-the-skin injection with instillation, said urologic surgeon Harry Herr of Memorial Sloan-Kettering Cancer Center in New York, “because we thought that systemic immunization was important.” The results had suggested there was no benefit to including the injection. But, says Albert, that was because the two techniques were performed simultaneously. “They didn’t yet have the immunological concept of priming and then boosting,” he explained.

The new results suggest “that we have to do this [the BCG immunization] before the intravesicle administration,” said Herr, “and that makes immunologic sense.”

It is possible that even a childhood TB vaccination may offer this later-in-life bladder cancer treatment benefit. However, as Albert pointed out, about 50 percent of people who have been vaccinated as kids lose their immunity. It would thus make more sense to vaccinate, or re-vaccinate, bladder cancer patients just prior to receiving BCG instillation therapy.

By giving this prior injection “we should get more bang for our buck,” said O’Donnell. "It will need to be tested in a clinical trial, of course, but I think this paper provides a very strong basis for doing such a trial.”

 

C. Biot et al., “Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer,” Science Translational Medicine, doi: 10.1126/scitranslmed.3003586, 2012.

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Touscents

Touscents

Posts: 1457

June 7, 2012

Terrific article!

June 7, 2012

My goodness.  Recruitment of a T cell response in a local environment results in T cell responses to other, unrelated antigens in the same immediate environment.  Who wudda thunked? 

So maybe that's why they use BCG in Freund's adjuvant?   

Perhaps rather than merely doing experiments and cataloguing the outcome results, scientists should also be doing critical thinking and analysis, and bringing various pieces of prior knowledge to bear on their work.  Once upon a time, a long time ago, they used to do that kind of thing. 

Avatar of: Naqwi

Naqwi

Posts: 1

June 7, 2012

As I understand, patients with pre-existing BCG immunity are currently not given intravesicle BCG. Instead, they are treated with intravesicle mytomycin C. Is this article suggesting that these patients too be given intravesicle BCG (knowing that immune response in these patients can be pretty strong)?

Avatar of: valid1

valid1

Posts: 2

June 7, 2012

I was given both in 1997. So far , so good.

Avatar of: valid1

valid1

Posts: 2

June 7, 2012

I had both in 1997. So far, so good.

Avatar of: Willy Sarti

Willy Sarti

Posts: 1457

June 7, 2012

I would like to suggest that the skin injection sould be make with Freund's adjuvant as it seems to be a strongest immune stimulator

June 11, 2012

We think that the skin injection has to match the bladder instillation - that said, Freund's does contain mycobacterial extract. Could be worth trying. Thanks. 

June 11, 2012

It is correct that patients are typically tested for their "pre-existing BCG immunity." If the reaction is VERY strong, it is considered an allergic or hyperactive response. As a result, patients are directed to mitomycin. The "pre-existing BCG immunity" referred to in this study was a normal response (10 - 40mm induration). 

June 11, 2012

In fact, they are related - BCG is given intradermally and then used again as intravesical therapy. What is curious is that the BCG-specific responses may be triggering anti-tumor responses, but this will require additional experiments. All the critical thinking in the world will not provide the concrete evidence that is required. Thanks for the comments. 

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Horizon Discovery
Horizon Discovery
Advertisement
NeuroScientistNews
NeuroScientistNews
Life Technologies